Spheno-Orbital Plasmacytoma as an Initial Presentation of Multiple Myeloma.

Brain Tumor Res Treat

Department of Neurosurgery, Pusan National University Hospital, Pusan National University College of Medicine, Busan, Korea.

Published: October 2022

Intracranial plasmacytoma is a rare neoplasm and a subtype of malignant plasma cell tumor. Most patients with plasma cell tumors are diagnosed with multiple myeloma, but 5%-10% of patients are not. This report includes descriptions of radiologic and clinical findings in a patient with intracranial plasmacytoma. Intracranial extra-axial plasmacytomas can be easily misdiagnosed as meningioma in radiologic and clinical findings. A 69-year-old woman presented with exophthalmos and diplopia, and MRI indicated meningioma. Thus, she underwent gross total resection, and her pathologic diagnosis was plasmacytoma. Exophthalmos and diplopia were fully recovered. She was finally diagnosed with multiple myeloma based on systemic evaluation and treated with targeted chemotherapy. MRI conducted at 3 months after surgery showed no local recurrence or remnant tumor. Although intracranial plasmacytomas are difficult to distinguish from meningiomas in preoperative evaluation, gross total resection is recommended for the same purposes as meningiomas. If the pathologic diagnosis is a plasmacytoma, it is essential to have a systemic evaluation for multiple myeloma.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9650124PMC
http://dx.doi.org/10.14791/btrt.2022.0026DOI Listing

Publication Analysis

Top Keywords

multiple myeloma
16
intracranial plasmacytoma
8
plasma cell
8
diagnosed multiple
8
radiologic clinical
8
clinical findings
8
exophthalmos diplopia
8
gross total
8
total resection
8
pathologic diagnosis
8

Similar Publications

Background: There is no standard treatment to accelerate recovery from melphalan-induced thrombocytopenia in multiple myeloma (MM) patients undergoing autologous stem cell transplantation (ASCT). Romiplostim, a thrombopoietin receptor agonist, has been developed to upregulate platelet production.

Objective: This study aimed to assess the efficacy and safety of romiplostim in reducing platelet transfusions post-ASCT in MM patients.

View Article and Find Full Text PDF

Ixazomib-induced angioedema.

Int J Hematol

January 2025

Department of Dermatology, Ogawa Red Cross Hospital, 1525 Ogawa, Ogawa-machi, Hiki-gun, Saitama, 355-0397, Japan.

View Article and Find Full Text PDF

Purpose: Orvacabtagene autoleucel (orva-cel; JCARH125), a CAR T-cell therapy targeting B-cell maturation antigen (BCMA), was evaluated in relapsed/refractory multiple myeloma (RRMM) patients in the EVOLVE phase 1/2 study (NCT03430011). We applied a modified piecewise model to characterize orva-cel transgene kinetics and assessed the impact of various covariates on its pharmacokinetics (PK).

Experimental Design: The population PK analysis included 159 patients from the EVOLVE study.

View Article and Find Full Text PDF

Rare cancer survivorship research funding at the National Institutes of Health (NIH), 2017 to 2023.

Cancer Causes Control

January 2025

Office of Cancer Survivorship, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA.

Purpose: Rare cancers are defined as those for which there are less than 15 cases per 100,000 in the population annually. While much progress in detection and treatment has been made over the past decade for many rare cancers, less progress has been made in understanding survivorship needs. The objective of this study was to characterize the National Institutes of Health (NIH) cancer survivorship grant portfolio focused on rare cancers and to identify gaps specific to this area of science.

View Article and Find Full Text PDF

Are we maintaining minimal residual disease in myeloma?

Leuk Lymphoma

January 2025

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.

Minimal residual disease (MRD) has emerged as an important prognostic maker in patients with multiple myeloma at different stages of their treatment. Moreover, it is being increasingly incorporated as an endpoint in various clinical trials. Since maintenance therapy is an integral part of myeloma treatment, especially in the upfront setting post autologous transplantation, it is imperative to understand the role of MRD testing in the maintenance stetting.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!